secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0000950170-25-003859
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine discloses ITGC material weakness; outlines bitopertin NDA plan and 2025 milestones
--------------------------------------------------------------------------------

- Material weakness in ITGC over key financial IT systems; no misstatements identified to date.
- Bitopertin NDA submission plans to be discussed after Type C FDA meeting in Q1 2025; potential accelerated approval for EPP.
- Initial phase 2 data for DISC-0974 in myelofibrosis anemia expected H2 2025; multiple-dose CKD data also H2 2025.
- Phase 2 trial of DISC-3405 in polycythemia vera planned to start H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000095017025003859/0000950170-25-003859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000095017025003859/iron-20250110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-003859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer